AFT hits US approval target, triggers cash

AFT hits US approval target, triggers cash
Managing director Hartley Atkinson said Maxigesic was an effective alternative for the US$700 million of IV paracetamol sold each year. (Photo: supplied).
Dan Brunskill
The United States medical regulator has accepted an application for AFT Pharmaceuticals’ patented pain relief medicine, which if approved would open up a more than US$300 million market.The US Food and Drug Administration has formally received the application for Maxigesic IV, an intravenous form of AFT’s painkiller, which was filed in August this year.Filing with the FDA triggers milestone payments worth US$3.6m under a licensing deal with US partner Hikma Pharmaceuticals. This will be recognised in the first half of the current fi...

More Markets

Ryman, Fletcher lift as market ends 9-day winning streak
Markets

Ryman, Fletcher lift as market ends 9-day winning streak

Market down despite Fletcher Building and Ryman Healthcare rising.

Tom Raynel 06 Nov 2025
Allied Farmers shareholders back sale of NZ Farmers Livestock
Primary Sector

Allied Farmers shareholders back sale of NZ Farmers Livestock

Allied will hold $14m in reserves as it looks for its next investment opportunity.

Staff reporters 06 Nov 2025
BNZ profit dips as economic return proves sluggish
Finance

BNZ profit dips as economic return proves sluggish

Net-interest margin tiptoes higher but total operating income slips. 

Andy Macdonald 06 Nov 2025
Commerce Commission approves Huntly agreement
Markets

Commerce Commission approves Huntly agreement

Gentailer deal to keep Rankine unit running gets a quick tick.

Ian Llewellyn 06 Nov 2025